tiprankstipranks
Autolus Therapeutics (AUTL)
NASDAQ:AUTL
US Market
AUTL
Autolus Therapeutics
RESEARCH TOOLSreports
Want to see AUTL full AI Analyst Report?

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

957 Followers
See the Price Targets and Ratings of:

AUTL Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Autolus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AUTL Stock 12 Month Forecast

Average Price Target

$8.08
▲(405.00% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $8.08 with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 405.00% change from the last price of $1.60.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,2.126153846153846,2.7823076923076924,3.4384615384615382,4.094615384615384,4.75076923076923,5.406923076923077,6.063076923076922,6.7192307692307685,7.375384615384615,8.031538461538462,8.687692307692307,9.343846153846153,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,1.9784615384615385,2.486923076923077,2.9953846153846158,3.503846153846154,4.012307692307693,4.520769230769231,5.02923076923077,5.537692307692308,6.046153846153847,6.554615384615385,7.063076923076923,7.571538461538462,{"y":8.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,1.7415384615384615,2.013076923076923,2.2846153846153845,2.556153846153846,2.827692307692308,3.0992307692307692,3.370769230769231,3.6423076923076927,3.913846153846154,4.185384615384615,4.456923076923077,4.728461538461539,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$8.08Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on AUTL
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$5
Buy
212.50%
Upside
Reiterated
05/15/26
Wells Fargo Remains a Buy on Autolus Therapeutics (AUTL)
Goldman Sachs Analyst forecast on AUTL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$6.1→$5.4
Buy
237.50%
Upside
Assigned
05/15/26
Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
Needham Analyst forecast on AUTL
Gil Blum
Needham
Needham
$10
Buy
525.00%
Upside
Reiterated
05/14/26
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
William Blair Analyst forecast on AUTL
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/14/26
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
H.C. Wainwright Analyst forecast on AUTL
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$9→$10
Buy
525.00%
Upside
Assigned
05/13/26
Autolus Therapeutics price target raised to $10 from $9 at H.C. WainwrightAutolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
Mizuho Securities Analyst forecast on AUTL
Salim Syed
Mizuho Securities
Mizuho Securities
$12→$10
Buy
525.00%
Upside
Assigned
03/30/26
Autolus Therapeutics price target lowered to $10 from $12 at MizuhoAutolus Therapeutics price target lowered to $10 from $12 at Mizuho
Truist Financial Analyst forecast on AUTL
Asthika Goonewardene
Truist Financial
Truist Financial
$10→$8
Buy
400.00%
Upside
Reiterated
01/13/26
Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on AUTL
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$5
Buy
212.50%
Upside
Reiterated
05/15/26
Wells Fargo Remains a Buy on Autolus Therapeutics (AUTL)
Goldman Sachs Analyst forecast on AUTL
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$6.1→$5.4
Buy
237.50%
Upside
Assigned
05/15/26
Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
Needham Analyst forecast on AUTL
Gil Blum
Needham
Needham
$10
Buy
525.00%
Upside
Reiterated
05/14/26
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
William Blair Analyst forecast on AUTL
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
05/14/26
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
H.C. Wainwright Analyst forecast on AUTL
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$9→$10
Buy
525.00%
Upside
Assigned
05/13/26
Autolus Therapeutics price target raised to $10 from $9 at H.C. WainwrightAutolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
Mizuho Securities Analyst forecast on AUTL
Salim Syed
Mizuho Securities
Mizuho Securities
$12→$10
Buy
525.00%
Upside
Assigned
03/30/26
Autolus Therapeutics price target lowered to $10 from $12 at MizuhoAutolus Therapeutics price target lowered to $10 from $12 at Mizuho
Truist Financial Analyst forecast on AUTL
Asthika Goonewardene
Truist Financial
Truist Financial
$10→$8
Buy
400.00%
Upside
Reiterated
01/13/26
Truist Financial Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Autolus Therapeutics

3 Months
Gil BlumNeedham
Success Rate
16/34 ratings generated profit
47%
Average Return
+5.75%
Copying Gil Blum's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +5.75% per trade.
1 Year
Gil BlumNeedham
Success Rate
16/34 ratings generated profit
47%
Average Return
+2.55%
Copying Gil Blum's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +2.55% per trade.
2 Years
Gil BlumNeedham
Success Rate
14/34 ratings generated profit
41%
Average Return
-13.84%
Copying Gil Blum's trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of -13.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUTL Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
12
9
8
8
10
Buy
3
2
2
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
11
10
10
13
In the current month, AUTL has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AUTL average Analyst price target in the past 3 months is 8.08.
Each month's total comprises the sum of three months' worth of ratings.

AUTL Financial Forecast

AUTL Earnings Forecast

Next quarter’s earnings estimate for AUTL is -$0.23 with a range of -$0.31 to -$0.18. The previous quarter’s EPS was -$0.27. AUTL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AUTL has Performed in-line its overall industry.
Next quarter’s earnings estimate for AUTL is -$0.23 with a range of -$0.31 to -$0.18. The previous quarter’s EPS was -$0.27. AUTL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AUTL has Performed in-line its overall industry.

AUTL Sales Forecast

Next quarter’s sales forecast for AUTL is $30.08M with a range of $28.80M to $32.43M. The previous quarter’s sales results were $26.17M. AUTL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AUTL has Performed in-line its overall industry.
Next quarter’s sales forecast for AUTL is $30.08M with a range of $28.80M to $32.43M. The previous quarter’s sales results were $26.17M. AUTL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AUTL has Performed in-line its overall industry.

AUTL Stock Forecast FAQ

What is AUTL’s average 12-month price target, according to analysts?
Based on analyst ratings, Autolus Therapeutics’s 12-month average price target is 8.08.
    What is AUTL’s upside potential, based on the analysts’ average price target?
    Autolus Therapeutics has 405.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AUTL a Buy, Sell or Hold?
          Autolus Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Autolus Therapeutics’s price target?
            The average price target for Autolus Therapeutics is 8.08. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $5.00. The average price target represents 405.00% Increase from the current price of $1.6.
              What do analysts say about Autolus Therapeutics?
              Autolus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of AUTL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.